Literature DB >> 15451148

Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction.

Amir Kashani1, Robert P Giugliano, Elliott M Antman, David A Morrow, C Michael Gibson, Sabina A Murphy, Eugene Braunwald.   

Abstract

AIMS: To define the clinical characteristics, co-morbidities, treatment, and clinical outcomes of patients with varying degrees of heart failure (HF) complicating ST-elevation myocardial infarction (STEMI), and to identify patients at high risk for HF following fibrinolysis. METHODS AND
RESULTS: 15,078 STEMI patients enrolled in a worldwide fibrinolytic trial (InTIME-II) were categorised into one of four hierarchical, mutually exclusive groups of HF: shock (n = 719, 5%); severe HF (n = 1082, 7%); mild HF (n = 1619, 11%); no HF (n = 11,658, 77%). In a multivariable model, anterior MI (OR 1.8, 95% CI [1.6; 1.9]), age > or = 65 (OR 1.8 [1.6; 2.0]), prior HF (OR 3.3 [2.6; 4.2]), and creatinine clearance < 60 mL/min (OR 1.8 [1.6; 2.1]) were the four most powerful correlates of HF. Although 30-day mortality was sixfold higher for patients with HF (18.9% vs. 3.1%, P < 0.0001), these patients were less likely to undergo angiography (30% vs. 40%, P < 0.0001) and revascularisation (19% vs. 25%, P , 0.0001), than patients without HF. Likewise, angiotensin-inhibitors and beta-blockers were not optimally utilised in patients with HF following MI.
CONCLUSIONS: During the index admission following fibrinolysis 23% of patients had HF. Despite a higher risk profile, patients with more severe HF were treated less aggressively than patients without HF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451148     DOI: 10.1016/j.ehj.2004.05.009

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.

Authors:  R Weir; J J V McMurray
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

Review 2.  Therapies to prevent heart failure post-myocardial infarction.

Authors:  Kevin L Thomas; Eric J Velazquez
Journal:  Curr Heart Fail Rep       Date:  2005-12

Review 3.  Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction.

Authors:  Robin A P Weir; John J V McMurray
Journal:  Curr Heart Fail Rep       Date:  2006-12

Review 4.  Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure.

Authors:  Shannon M Dunlay; Véronique L Roger
Journal:  Curr Heart Fail Rep       Date:  2012-12

5.  ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy.

Authors:  Carmine Riccio; Michele Massimo Gulizia; Furio Colivicchi; Andrea Di Lenarda; Giuseppe Musumeci; Pompilio Massimo Faggiano; Maurizio Giuseppe Abrignani; Roberta Rossini; Francesco Fattirolli; Serafina Valente; Gian Francesco Mureddu; Pier Luigi Temporelli; Zoran Olivari; Antonio Francesco Amico; Giancarlo Casolo; Claudio Fresco; Alberto Menozzi; Federico Nardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

6.  Acute heart failure with and without acute coronary syndrome: clinical correlates and prognostic impact (From the HEARTS registry).

Authors:  Hussam AlFaleh; Abdelfatah A Elasfar; Anhar Ullah; Khalid F AlHabib; Ahmad Hersi; Layth Mimish; Ali Almasood; Saleh Al Ghamdi; Abdullah Ghabashi; Asif Malik; Gamal A Hussein; Mushabab Al-Murayeh; Ahmed Abuosa; Waleed Al Habeeb; Tarek S Kashour
Journal:  BMC Cardiovasc Disord       Date:  2016-05-20       Impact factor: 2.298

7.  Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database.

Authors:  Ting-Tse Lin; K Arnold Chan; Ho-Min Chen; Chao-Lun Lai; Mei-Shu Lai
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.